Tag: Lisa Roth MD

Dr. Lisa Roth and the Treatment of Burkitt Lymphoma

The Meyer Cancer Center recently profiled Dr. Lisa Roth and the far-reaching impact of her work in finding new targeted therapies to treat young patients with Burkitt lymphoma. Burkitt’s is an aggressive form of non-Hodgkin lymphoma that is often fatal. Finding alternative therapy options is important because,

“As many as 85 percent of children with Burkitt lymphoma respond well to treatment. Their tumors grow incredibly fast – doubling in size in a matter of days – but also shrink incredibly fast when blasted with high-dose chemotherapy. In order to ensure the tumors don’t return, they undergo intensive sustained treatment that generally lasts from 4-8 months.”

“For those who don’t respond, however, or for those whose disease returns despite the treatment, the survival rate is below 20 percent. And success is often tempered by immediate and long-term side effects, including cardiovascular problems, infertility and secondary malignancies.”

“We do very well, curing the majority of patients; the problem is the amount of chemotherapy needed to get to that cure rate is substantial,” Roth said. “As our patients are surviving longer and longer, we are beginning to see the toll the treatments are taking long-term.”

To this end Dr. Roth has received funding from the St. Baldrick’s Foundation to investigate PU-H71 a promising new therapy which kills Burkitt lymphoma cells by attacking a protein required for suvival.

Besides her work in finding new options to treat Burkitt lymphoma, Dr. Roth is building an adolescent and young adult lymphoma program at Weill Cornell Medicine. The program will focus on the needs of patients who don’t squarely fit into either the pediatric or adult categories for treatment. It will also specifically address the needs of young adult patients like fertility.

Look to this space for more information about the adolescent and young adult lymphoma program at Weill Cornell Medicine.

If you are interested in making an appointment with Dr. Roth and the adolescent and young adults lymphoma program you can call her at 646-962-2068

REDLAMP 7: Parenthood in Adult Female Survivors Treated for Hodgkin Lymphoma as a Child & Teenager

Lancet Oncology recently published a study comparing the frequency of parenthood in women who were diagnosed with Hodgkin lymphoma as a child or adolescent and a female population control group. In this video Dr. Lisa Roth discusses the implications of these findings regarding future fertility for women previously diagnosed with Hodgkin lymphoma as a child or adolescent.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Dr. Lisa Roth Describes a Clinical Trial Testing Nivolumab in Patients with Hodgkin Lymphoma who Relapsed after an Autologous Stem Cell Transplant

In this video Dr. Lisa Roth explains the benefits of a phase II trial for men and women with Hodgkin lymphoma whose disease has relapsed after an autologous stem cell transplant. The purpose of this study is to evaluate the clinical benefits of nivolumab in people with relapsed Hodgkin lymphoma. This trial is sponsored by Bristol-Myers Squibb.

If you’re interested in participating in this trial please call 646-962-2074 for more information. A full listing of Hodgkin lymphoma trials at Weill Cornell Medical College can be found here.